The effect of dexamethasone on fibrinolytic parameters of ram lymphocytes

Small Ruminant Research

Volumn 32, Issue 3, 1999, Pages 279-284

  Tsantarliotou, M ^a   Goulas, P ^b   Milonas, Ch ^b   Kokolis, N ^a   Smokovitis, A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b TECHNOLOGICAL EDUCATIONAL INSTITUTE OF LARISSA   (Greece)

Author keywords

Dexamethasone; Lymphocytes; Plasmin inhibition; Plasminogen activator; Plasminogen activator inhibition

Indexed keywords

EID: 0032966384     PISSN: 09214488     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0921-4488(98)00193-X     Document Type: Article

References (35)

1. Bohuslav J., Horejsi V., Hansmann C., Stöckl J., Weidle U.H., Majdic O., Bartke I., Knapp W., Stockinger H. Urokinase plasminogen activator receptor, ß2-integrins, and src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181:1995;1381-1390.
2. Busso N., Belin D., Failly-Crepin C., Vassalli J.-D. Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100). J. Biol. Chem. 261:1986;9309-9315.
3. Daniel, W.W., 1991. Biostatistics: A Foundation for Analysis in the Health Sciences, 5th edn., Wiley, New York, pp. 138-143.
4. Danø K., Andreasen P.A., Grøndahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:1985;139-266.
5. Deutsch D.G., Mertz E.T. Plasminogen: Purification from human plasma by affinity chromatography. Science. 170:1970;1095-1096.
6. Felez J., Miles L.A., Fabregas P., Jardi M., Plow E.F., Lijnen R.H. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by t-PA on the surface of leukocytic cells. Thromb. Haemost. 76:1996;577-584.
7. Gadd S.J., Madjik O., Kasinreck W., Stockinger H., Maurer D., Eher R., Knapp W. M5, a phosphoinositol-linked human myelomonocytic activation-associated antigen. Clin. Exp. Immunol. 80:1990;252-256.
8. Gordon S. Macrophage neutral proteinases and defense of the lung. Fed. Proc. 36:1977;2707-2711.
9. Granelli-Piperno A., Reich E. Plasminogen activators of the pituitary gland: Enzyme characterization and hormonal modulation. J. Cell Biol. 97:1983;1029-1037.
10. Gundersen D., Tran-Thang C., Sordat B., Mourali F., Ruegg C. Plasmin-induced proteolysis of tenascin-c: Modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J. Immunol. 158:1997;1051-1060.
11. Hamilton J.A., Whitty G.A., Stanton H., Wojta J., Gallichio M., McGrath K., Ianches G. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen activator inhibitors by human monocytes. Blood. 82:1993;3616-3621.
12. Hart P.H., Vitti G.F., Burgess D.R., Singleton D.K., Hamilton J.A. Human monocytes can produce tissue-type plasminogen activator. J. Exp. Med. 169:1989;1509-1514.
13. Higazzi A.A.-R., Barghouti I.I., Abu-Much R. Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. J. Biol. Chem. 270:1995;9472-9477.
14. Hoyer-Hansen G., Ronne E., Solberg H., Behrendt N., Ploug M., Lund L.R., Eliis V., Danø K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267:1992;18224-18229.
15. Jardi M., Ingles-Esteve J., Burgal M., Azqueta C., Velasko F., Lopez-Pedrera C., Miles L.A., Felez J. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thromb. Haemost. 76:1996;1009-1019.
16. Littlefield B.A., Johnston L.J., Manzer D.S., Roche P.C. Glucocorticoid inhibition of urokinase-like plasminogen activators in cultured human lymphoblasts. Endocrinology. 117:1985;1100-1109.
17. Loskutoff D.J., Roegner K., Erickson L.A., Schleef R.R., Huttenlocher A., Coleman P.L., Gelehrter T.D. The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically related to an inhibitor produced by bovine aortic endothelial cells. Thromb. Haemost. 55:1986;8-11.
18. Lund L.R., Rømer J., Rønne E., Ellis V., Blasi F., Danø K. Urokinase-receptor biosynthesis, m-RNA level and gene transcription are increased by transforming growth factor in human A549 lung carcinoma cells. EMBO J. 10:1991;3399-3407.
19. McDonald, L.E., 1980. Veterinary Endocrinology and Reproduction, Lea and Febiger, Philadelphia, PA, pp. 192.
20. Melcher, F., 1991. Annual Report, Basel Institute for Immunology, Basel, Switzerland.
21. Menkin, V., 1938, cited by Higazzi, A.A.-R., Barghouti, I.I., Abu-Much, R., 1995. Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. J. Biol. Chem. 270, 9472-9477.
22. Miles L.A., Plow E.F. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thromb. Haemost. 58:1987;936-942.
23. Nykjaer A., Møller B., Todd R.F. III, Christensen T., Andreasen P.A., Gliemann J., Petersen C.M. Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol. 152:1994;505-516.
24. Plow E.F., Edgington T.S. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leucocyte proteases at physiological pH. J. Clin. Invest. 56:1975;30-38.
25. Reiter L.S., Spertini O., Kruithof E.K.O. Plasminogen activators play an essential role in extracellular matrix invasion by lymphoblastic T-cells. Int. J. Cancer. 70:1997;461-466.
26. Saldeen, T., 1979. The microembolism syndrome, In: Saldeen, T. (Ed.), The Microembolism Syndrome, Almqvist and Wiksell, Stockholm, pp. 7-44.
27. Smokovitis A., Kokolis N., Alexopoulos C., Alexaki E., Eleftheriou E. Plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition in spermatozoa and seminal plasma of man and various animal species - Effect of plasmin on sperm motility. Fibrinolysis. 1:1987;253-257.
28. Smokovitis A., Kokolis N., Ploumis Th. Great variation in the response of tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition to endotoxin, aspirin and endotoxin after administration of aspirin. Thromb. Res. 50:1988;495-505.
29. Smokovitis A., Kokolis N., Rekkas C., Ploumis Th. Variable response of tissue parameters of the fibrinolytic system to unilateral or bilateral adrenalectomy and unilateral or bilateral adrenal demedullation. J. Endocrinol. Invest. 14:1991;815-820.
30. Stringer K.A., Bose S.K., McCord J.M. Anti-inflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Rad. Biol. Med. 22:1997;985-988.
31. Tsantarliotou, M., 1997. The effect of glucocorticoids and melatonin on the activity of spesialized proteases in spermatozoa and seminal plasma of the ram, Doctoral thesis (in Greek, with English abstract).
32. Vassali J.D., Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 214:1987;187-191.
33. Vassali J.D., Dayer J.M., Wohlweld A., Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocyte macrophages. J. Exp. Med. 159:1984;1653-1668.
34. Wang C., Leung A. Glucocorticoids stimulate plasminogen activator production by rat granulosa cells. Endocrinology. 124:1989;1595-1601.
35. Wilson E.L., Jacobs P., Dowdle E.B. The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human acute myeloid leukemia cells. Blood. 61:1983;561-574.